Home > Publications Database > Change in functional connectivity strength during rest and encoding is differentially related to Alzheimer's pathology and memory depending on APOE genotype > print

001     283067
005     20251230103620.0
024 7 _ |a 10.1002/alz70856_100192
|2 doi
024 7 _ |a pmid:41447082
|2 pmid
024 7 _ |a pmc:PMC12739621
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-01474
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fischer, Larissa
|0 P:(DE-2719)9002356
|b 0
|e First author
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Change in functional connectivity strength during rest and encoding is differentially related to Alzheimer's pathology and memory depending on APOE genotype
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767013771_31206
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a The medial temporal lobe (MTL) and posteromedial cortex (PMC) are essential for episodic memory and affected early by Alzheimer's pathology, particularly in APOE4 carriers. Functional connectivity (FC) changes within and between MTL and PMC could be detrimental or beneficial for cognition. However, the relation of those changes to Alzheimer's pathology and memory performance is unclear and most studies assess FC only during rest. We hypothesized that increasing FC strength would be associated with higher pathology burden, especially in APOE4 carriers.In this preregistered study, we analysed longitudinal 3-Tesla fMRI over up to 4 years and cross-sectional amyloid-beta and tau PET (PREVENT-AD cohort; details in Figure 1). We assessed changes in resting-state FC (RSFC) and task-FC during intentional object-location encoding within (ΔFCPMC, ΔFCMTL) and between MTL and PMC (ΔFCMTL-PMC). The sample included 152 cognitively unimpaired older adults (63±5years, 102 female, 59 APOE4). We investigated associations between ΔFC strength with i) pathology burden and ii) change in delayed memory (RBANS composite score and fMRI-task object recognition), and interactions with APOE genotype. We used multiple regression and linear mixed models including APOE, age, sex and education.We found ΔFC by APOE interactions predicting pathology. Specifically, declining RSFCPMC (p = 0.038; Figure 2a) was related to more global amyloid in APOE4 carriers only. In contrast, increasing encoding-FCMTL was related to more entorhinal tau in APOE4 carriers only (p = 0.032, Figure 2b). Regarding cognition, regardless of APOE status, increasing encoding-FCPMC was related to decreasing RBANS (p = 0.018) performance and object recognition (p = 0.001). Finally, increasing RSFCMTL-PMC was related to increasing RBANS performance (p = 0.032; Figure 3a), but increasing encoding-FCMTL-PMC was related to decreasing object recognition (p = 0.014; Figure 3b).Our study shows APOE-dependent and region-specific associations of ΔFC strength within and between episodic memory areas with pathology burden and memory performance. Notably, associations differed between RSFC and task-FC. In APOE4 carriers, longitudinally increasing FC or 'hyperconnectivity' within MTL during encoding was related to tau in line with our hypothesis. However, in PMC, longitudinally decreasing FC during rest was related to more amyloid, indicating a disconnection in PMC regions. Our study highlights that pathology-related network changes manifest differentially during rest and task (memory encoding).
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Apolipoprotein E4
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Biomarkers: metabolism
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Temporal Lobe: diagnostic imaging
|2 MeSH
650 _ 2 |a Temporal Lobe: pathology
|2 MeSH
650 _ 2 |a Temporal Lobe: metabolism
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
700 1 _ |a Adams, Jenna N
|b 1
700 1 _ |a Molloy, Eóin N.
|0 P:(DE-2719)9002180
|b 2
700 1 _ |a Tremblay-Mercier, Jennifer
|b 3
700 1 _ |a Remz, Jordana
|b 4
700 1 _ |a Binette, Alexa Pichet
|b 5
700 1 _ |a Rajah, Natasha
|b 6
700 1 _ |a Villeneuve, Sylvia
|b 7
700 1 _ |a Maass, Anne
|0 P:(DE-2719)2811815
|b 8
|e Last author
700 1 _ |a Group, PREVENT-AD Research
|b 9
|e Collaboration Author
773 _ _ |a 10.1002/alz70856_100192
|g Vol. 21 Suppl 2, no. Suppl 2, p. e100192
|0 PERI:(DE-600)2201940-6
|n Suppl 2
|p e100192
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283067/files/DZNE-2025-1474.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283067/files/DZNE-2025-1474.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283067
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002356
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002180
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811815
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1311001
|k AG Maaß
|l Multimodal Neuroimaging
|x 0
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1311001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21